PubRank

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (QUIREDEX)

Clinical Trial ID NCT00480363

PubWeight™ 12.88‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00480363

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003 14.41
2 Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994 6.48
3 Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013 6.21
4 Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005 5.82
5 Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001 4.76
6 Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002 4.56
7 Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999 3.99
8 A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006 3.89
9 Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999 3.87
10 Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000 2.87
11 New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007 2.77
12 Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998 2.39
13 Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003 2.02
14 Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002 1.76
15 Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2013 1.51
16 Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol 2016 1.39
17 Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011 1.37
18 Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993 1.32
19 Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996 1.26
20 Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003 1.24
21 MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology Am Soc Hematol Educ Program 2005 1.23
22 Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997 1.13
23 Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993 1.12
24 Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995 1.08
25 Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000 1.07
26 Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005 0.99
27 Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. I. Eur J Haematol 1991 0.89
28 Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide? Haematologica 2012 0.82
29 Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood 2015 0.81
30 Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol 2010 0.78
Next 100